LANREOTIDE ACETATE
Generic: LANREOTIDE ACETATE
Cipla USA Inc.Manufacturer
SUBCUTANEOUSRoute
LANREOTIDE ACETATEActive Substance
2024-05-21Original Approval
LANREOTIDE ACETATE is FDA application ANDA217193, sponsored by INVAGEN PHARMS. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2026-03-13
Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only, Rx Only, Manufactured by: PharLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for def
Class II2026-01-02
Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, ManufacturPresence of Particulate Matter.
Class II2026-03-13
Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 safety needle, Single dose only, Rx Only, Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for def
Top Reported Reactions
1
DEATH
1,038 reports
2
OFF LABEL USE
943 reports
3
DIARRHOEA
596 reports
4
FATIGUE
454 reports
5
ABDOMINAL PAIN
347 reports
6
NAUSEA
328 reports
7
MALIGNANT NEOPLASM PROGRESSION
327 reports
8
WEIGHT DECREASED
281 reports
9
MALAISE
270 reports
10
ASTHENIA
269 reports